AXAM Therapeutics Company Profile, Contacts & Intelligence

AXAM Therapeutics Overview

AXAM Therapeutics explores the epigenetic paradigm to disrupt the drug discovery concepts in human chronic diseases. Our vision took the source from the pioneering work of the founder Khelifa Arab at the German Cancer Research Center (DKFZ) and Institute of Molecular Biology Mainz (IMB) on the epigenetic regulation of tumor and metastasis suppressor genes by regulatory RNAs and R-loops structures. AXAM developed novel tools to define tumor epigenome weakness that enable us to select target proteins suitable for innovative drug development, i.e, small molecules and/or biologics. AXAM spearheaded a research therapeutic program in oncology and gathered two experienced cancer epigenetics and business strategy members in a creative team, aiming to reinforce the team with digital chemistry and drug developer experts. AXAM Therapeutics aims to fight against lethal chronic diseases and reinvest profits into sustainable epigenetic research.

Headquarters

Mainz, Rheinland-pfalz, De

Industry

Biotechnology Research

Founded

2022

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

AXAM Therapeutics Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

AXAM Therapeutics People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Compare Similar Companies to AXAM Therapeutics

Explore companies in related markets and compare their industry and employee estimates.